Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Go back to Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder| (NASDAQ: VTGN) | Delayed: 0.37 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.37 | 52 Week High | $4.60 | |||
| Open | $0.37 | 52 Week Low | $2.81 | |||
| Day High | $0.37 | P/E | N/A | |||
| Day Low | $0.37 | EPS | $0.00 | |||
| Volume | 3,080,701 | |||||
